Transderm Scop

(Scopolamine)

ApprovedSmall molecule

Transderm Scop is a small molecule that works as a Muscarinic Acetylcholine Receptor M1 Antagonist.[2] It is being used across 13 indications, with its most advanced program in Approved.[1]

Transderm Scop is one of 323 small molecule programs targeting Nicotine Dependence. It is currently in Approved.

Indications

Total Trials

Active Trials

322

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceActive, not recruiting

Depressive DisorderApproved

Post Operative Nausea and VomitingActive, not recruiting

Alzheimer DiseaseApproved

Renal ColicApproved

Nausea and VomitingCompleted

Amyotrophic Lateral SclerosisApproved

Social Anxiety DisorderCompleted

MemoryEnrolling by invitation

Major Depressive DisorderApproved

Nicotine DependencePreclinical

Active, not recruiting

Depressive DisorderApproved

Approved

Post Operative Nausea and VomitingApproved

Active, not recruiting

Alzheimer DiseaseApproved

Approved

Renal ColicApproved

Approved

Nausea and VomitingApproved

Completed

Amyotrophic Lateral SclerosisApproved

Approved

Social Anxiety DisorderApproved

Completed

MemoryPhase 1

Enrolling by invitation

Major Depressive DisorderApproved

Approved

Showing 10 of 12 indications

Competition

Competitive Landscape

115 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Geodon

Pfizer

Approved

3 2

Ajovy

Teva

Approved

1 3

Victoza

Novo Nordisk

Approved

—4

Transderm Scop

BBaxter Healthcare Corporation

Approved

1 5

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 6

Ketalar

Boehringer Ingelheim

Phase 3

5 7

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 8

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 9

Psilocybin

Ssris

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Epilepsy

NCT05594017

Q3 2032

Phase 1Recruiting

Hallucinations

NCT04366518

Clinical

Trials by Indication[1]

Scopolamine8 trials

Nebulizer Delivery of Intranasal Scopolamine

Completed·—·Phase 1·NCT04999449·14 enrolled

Scopolamine in Healthy Volunteers

Unknown status·RRepurposed Therapeutics, Inc.·Phase 1·NCT03874130·130 enrolled

Scopolamine Challenge Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT01213355·38 enrolled

Show 5 more trials

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

Terminated·MMassachusetts General Hospital·Phase 2·NCT01312844·7 enrolled

Effects of Transdermal Scopolamine on Occupational Performance

Completed·—·Phase 2·NCT00374478·33 enrolled

The Antidepressant Efficacy of the Anticholinergic Scopolamine

Terminated·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00369915·17 enrolled

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

Withdrawn·YYale University·Phase 1·NCT06014385

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

Terminated·RRepurposed Therapeutics, Inc.·Phase 2/3·NCT02155309·63 enrolled

Nausea and vomiting5 trials

The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in MVD Surgery

Unknown status·SSeoul National University Hospital·Phase 4·NCT02968082·60 enrolled

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Completed·—·N/A·NCT00659737·115 enrolled

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Completed·—·N/A·NCT00717054·115 enrolled

Show 2 more trials

Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section

Completed·RRutgers, The State University of New Jersey·Phase 4·NCT02960113·240 enrolled

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Motion Sickness3 trials

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Completed·RRepurposed Therapeutics, Inc.·Phase 3·NCT03988530·98 enrolled

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

Unknown status·RRepurposed Therapeutics, Inc.·Phase 3·NCT04272255·300 enrolled

The Prevention and Treatment of Nausea Associated With Motion Sickness

Completed·RRepurposed Therapeutics, Inc.·Phase 3·NCT03986905·300 enrolled

Alzheimer's Disease1 trial

The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study

Completed·MMentis Cura·N/A·NCT02273895·29 enrolled

Hallucinations1 trial

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting·YYale University·Phase 1·NCT04366518·35 enrolled

20 more indications

Cognitive Function1 trial

Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI

Completed·HHebrew SeniorLife·N/A·NCT01379001·60 enrolled

Memory1 trial

Representation of Spatiotemporal Information in Human Episodic Memory and Navigation

Enrolling by invitation·UUniversity of Arizona·Phase 1·NCT07423923·15 enrolled

Tics1 trial

Anesthetics in Rhytidoplasty - A Comparison Study

Completed·MMercy Facial Plastic Surgery Center·N/A·NCT02410460·30 enrolled

Cognitive impairment1 trial

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Terminated· Takeda logo

Takeda·Phase 1·NCT02918266·18 enrolled

Major Depressive Disorder1 trial

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

Withdrawn·MMassachusetts General Hospital·N/A·NCT01613820

Efficacy and Safety1 trial

Efficacy and Safety of Escócia Association in the Treatment of Acute Pain

Withdrawn·EEMS·Phase 2·NCT04666701

Double-blind1 trial

A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness

Unknown status·MMedical Corps, Israel Defense Force·N/A·NCT01198106·100 enrolled

Bipolar Depression1 trial

Scopolamine in Bipolar Depression

Completed·—·Phase 2·NCT04211961·55 enrolled

Hand Surgery1 trial

A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery

Completed·—··NCT04008264·74 enrolled

Gastrointestinal1 trial

Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy

Unknown status·XXijing Hospital of Digestive Diseases·N/A·NCT02725398·150 enrolled

Adult1 trial

Mental Ability Challenge Study in Adults With and Without HIV

Completed·VVanderbilt University Medical Center··NCT03244488·22 enrolled

Nausea1 trial

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

Completed·SStony Brook University·Phase 4·NCT03435003·83 enrolled

Mood Disorder1 trial

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

Terminated·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00055575·197 enrolled

ESS1 trial

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Completed·DDaniela Moga·Phase 1·NCT02849639·90 enrolled

Cognitive Deficit1 trial

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02051335·27 enrolled

Safety and Efficacy1 trial

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

Unknown status·NNaval Aeromedical Research Unit, Dayton·Phase 3·NCT03920644·320 enrolled

Effectiveness1 trial

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

Completed·—·Phase 4·NCT03131050·66 enrolled

Epilepsy1 trial

Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05594017·60 enrolled

Obesity, Morbid1 trial

Multimodal Analgesia Effect on Post Surgical Patient

Completed·UUniversity of California, Davis·Approved·NCT04240626·60 enrolled

Unspecified1 trial

Generalization of Extinction Learning

Completed·UUniversity of California, Los Angeles·Phase 1·NCT01900301·60 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TRANSDERM SCOP

NDA NDA017874

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Scopolamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Scopolamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Scopolamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017874). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Muscarinic Acetylcholine Receptor M1 Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Transderm Scop

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2032

Trials by Indication[1]

Scopolamine8 trials

Nausea and vomiting5 trials

Motion Sickness3 trials

Alzheimer's Disease1 trial

Hallucinations1 trial

Cognitive Function1 trial

Memory1 trial

Tics1 trial

Cognitive impairment1 trial

Major Depressive Disorder1 trial

Efficacy and Safety1 trial

Double-blind1 trial

Bipolar Depression1 trial

Hand Surgery1 trial

Gastrointestinal1 trial

Adult1 trial

Nausea1 trial

Mood Disorder1 trial

ESS1 trial

Cognitive Deficit1 trial

Safety and Efficacy1 trial

Effectiveness1 trial

Epilepsy1 trial

Obesity, Morbid1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News